paclitaxel has been researched along with Bladder Cancer in 251 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 35 (13.94) | 18.2507 |
| 2000's | 123 (49.00) | 29.6817 |
| 2010's | 70 (27.89) | 24.3611 |
| 2020's | 23 (9.16) | 2.80 |
| Authors | Studies |
|---|---|
| Carlos, L; Colombo, P; De Cobelli, O; Duran-Merino, R; Guazzoni, G; Hurle, R; Lazzeri, M; Nohales, G; Santoro, A; Trapani, ED | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Albisinni, S; Awada, A; Barthelemy, P; Caparica, R; Carnot, A; Casert, V; Culine, S; Fantoni, JC; Gil, T; Gizzi, M; Martinez Chanza, N; Paesmans, M; Roumeguere, T; Sautois, B; Seront, E; Soukane, L; Staudacher, L; Tricard, T; Van den Brande, J; Vanhaudenarde, V | 1 |
| Kiyozuka, K; Kohei, N; Suzuki, R | 1 |
| Belmonte-Fernández, A; Flores, ML; González-Moreno, M; Japón, MÁ; Jiménez-Guerrero, R; Pérez-Valderrama, B; Romero, F; Sáez, C | 1 |
| Albany, C; Fleming, M; Galsky, MD; Gourdin, T; Hahn, NM; Hauke, R; Jana, B; Jun, T; MacVicar, GR; Oh, WK; Sonpavde, G; Taik, P; Uzilov, A; Varadarajan, AR; Wang, H | 1 |
| Bi, J; Wang, L; Wang, Y | 1 |
| Chen, Y; Han, R; Hao, Y; He, X; Liu, Q; Liu, T; Qian, Z; Yang, C; Yang, Y | 1 |
| Akasaka, S; Fujimoto, N; Hamasuna, R; Harada, KI; Harada, M; Harada, S; Matsumoto, H; Minato, A; Nagata, Y; Sakano, S; Terado, M; Tomisaki, I | 1 |
| Bae, WK; Byun, JH; Choi, YJ; Keam, B; Kim, M; Kim, S; Lee, HJ; Lee, JL; Ock, CY; Park, KH; Shin, SJ; Song, H; Youk, J | 1 |
| Hosomi, T; Makino, Y; Otsuka, H; Shibasaki, N; Shichiri, Y; Uketa, S | 1 |
| Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M | 1 |
| Hwang, I; Lee, JL; Park, I; Yoon, SK | 1 |
| Anand, K; Chiang, S; Duvic, M; Ensor, J; Hwu, P; Iyer, S; Miranda, R; Pingali, SR; Zu, Y | 1 |
| An, JH; Chae, HK; Lee, IH; Son, MH; Song, WJ; Yang, JI; Youn, HY | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Abe, T; Akino, T; Alam, MT; Ameda, K; Annan, DA; Azuma, M; Dawood, RIH; Harabayashi, T; Hida, K; Hida, Y; Ishizuka, K; Kashiwagi, A; Kikuchi, H; Maishi, N; Maruyama, S; Matsumoto, R; Matsuno, Y; Miyajima, N; Morimoto, M; Osawa, T; Sato, M; Shinohara, N; Takeda, R; Tsuchiya, K; Yamashiro, K | 1 |
| Chang, R; Kong, Z; Ma, X; Mao, G; Wang, F; Zhang, X | 1 |
| Kim, JH; Lee, JH; Lee, KH | 1 |
| Jia, M; Li, D; Li, H; Li, J; Li, X; Lin, P; Mo, L; Qiu, W; Su, B; Wang, D; Xu, L; Yang, B; Ying, J; Zhou, Z | 1 |
| Araki, M; Edamura, K; Iwata, T; Katayama, S; Kobayashi, Y; Nasu, Y; Nishimura, S; Sadahira, T; Sako, T; Takamoto, A; Wada, K; Watanabe, M; Watanabe, T | 1 |
| Childs, DS; Costello, BA; Pagliaro, LC; Quevedo, JF | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Chang, B; Dahl, DM; George, A; Hu, C; Lee, RJ; Lee-Wu, C; Michaelson, MD; Pham, HT; Sandler, H; Shipley, W; Souhami, L; Swanson, GP; Vuky, J | 1 |
| Matsuo, T; Miyata, Y; Nakamura, Y; Ohba, K; Sakai, H; Takehara, K; Yasuda, T | 1 |
| Horn, T; Krege, S; Retz, M | 1 |
| Gong, BS; Li, LJ; Qiu, MX; Wang, Y | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| Apolo, AB; Chowdhury, S; Galsky, MD; Hahn, NM; Merseburger, AS; Milowsky, MI; Petrylak, D; Powles, T; Quinn, DI; Rosenberg, JE; Siefker-Radtke, A; Sonpavde, G; Sternberg, CN | 1 |
| Chang, HC; Chow, PM; Hong, JY; Hsu, FS; Huang, KH; Kuo, KL; Liao, SM; Lin, JY; Lin, WC; Pan, CI; Shi, CS; Wu, JT; Yang, SP | 1 |
| Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
| Culine, S | 2 |
| Buti, S | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Bellmunt, J; Galsky, MD; Sonpavde, G | 1 |
| Canil, CM; Eisen, A; Elser, C; Ko, YJ; Mukherjee, SD; Reaume, MN; Sridhar, SS; Winquist, E; Zhang, L | 1 |
| Hudes, GR; Lee, J; Litwin, S; Plimack, ER; Song, W; Vaughn, D; Wong, YN | 1 |
| Payton, S | 1 |
| Kamat, AM | 1 |
| Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Hussain, M; Theodorescu, D | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Ahn, JJ; Badalato, GM; Barlow, LJ; Benson, MC; Decastro, GJ; Ghandour, RA; Holder, DD; Kates, M; McKiernan, JM; Roychoudhury, A | 1 |
| Deng, H; He, Y; Li, Y; Liu, Q; Lv, L; Meng, F; Pu, Y; Qian, L; Wang, Y; Xiao, J; Zhang, C; Zhang, D; Zhang, H; Zhao, W; Zhu, J | 1 |
| Ichimaru, N; Kojima, Y; Nonomura, N; Okumi, M; Takahara, S; Takahi, Y | 1 |
| Bai, H; Deng, Y; Hu, H | 1 |
| Ito, Y; Kikuchi, E; Kosaka, T; Miyajima, A; Mizuno, R; Oya, M; Shinojima, T; Suzuki, E; Tanaka, N; Umezawa, K | 1 |
| Ishihara, K; Kikuchi, E; Konno, T; Matsumoto, K; Miyajima, A; Oya, M; Tamura, K | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Papadopoulos, EI; Scorilas, A | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Banno, E; Kanno, N; Kino, S; Nagai, Y; Nishino, A; Tahara, H; Yasuda, M | 1 |
| Henderson, PT; Jiang, S; Lin, TY; Malfatti, M; Pan, AW; Pan, CX; Turteltaub, K; Zhang, H | 1 |
| Ishitoya, S; Onishi, H; Takeuchi, E; Terashima, T; Uemura, Y; Ushida, H | 1 |
| Boccardo, F; Colecchia, M; Dellepiane, C; Messina, C; Ravetti, GL; Spina, B; Tomasello, L; Zanardi, E | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Chen, NC; Chou, FP; Chyau, CC; Lee, YJ; Tseng, HC | 1 |
| Chen, Y; Cheng, K; Li, ZK; Li, ZP; Liu, JY; Yang, Y | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Cheng, M; Dall'Era, M; deVere White, R; Lam, KS; Lee, J; Li, T; Li, Y; Lin, TY; Pan, A; Pan, CX; Wang, F; Zhang, H | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Anderson, CB; DeCastro, GJ; Ghandour, R; Matulay, JT; McKiernan, JM; Robins, DJ; Sui, W | 1 |
| Bamias, A; Dimopoulos, MA; Horti, M; Kastritis, E; Kavantzas, N; Kyriakou, F; Legaki, S; Murray, S; Noni, A; Patsouris, ES; Tamvakis, N | 1 |
| Beekman, K; Dunn, RL; Hussain, M; Lee, CT; Mackler, NJ; Montie, JE; Petrylak, DP; Quinn, DI; Sanda, M; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Becker, A; Bolenz, C; Gabriel, U; Herrmann, E; Michel, MS; Steidler, A; Trojan, L; Weiss, C; Wenzel, M | 1 |
| Brooks, DE; Burt, HM; Gleave, ME; Hadaschik, BA; Kainthan, RK; Mugabe, C; So, AI | 1 |
| Kanai, K; Kikuchi, E; Miyajima, A; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Heney, NM; Kaufman, DS; Sandler, HM; Shipley, WU; Tanguay, S; Toonkel, LM; Wallace, HJ; Winter, KA; Zietman, AL | 1 |
| Autorino, R; Bellelli, T; De Placido, S; Di Lorenzo, G; Giannarini, G; Imbimbo, C; Longo, N; Mirone, V; Montesarchio, V; Morelli, E | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Bassi, P; Bongiovanni, L; Cappa, E; D'Agostino, D; Gardi, M; Pinto, F; Racioppi, M; Sacco, E; Totaro, A; Volpe, A | 1 |
| Cheng, AL; Cheng, JC; Hsu, CH; Hsu, FM; Huang, CY; Huang, KH; Lin, CC; Pu, YS; Tsai, YC | 1 |
| Bognar, Z; Farkas, L; Gallyas, F; Szabo, A; Szanto, A; Szigeti, A | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Bartel, P; Ecke, TH; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Boström, PJ; Laato, M; Laihia, JK; Leino, L; Pylkkänen, L | 1 |
| Ding, S; Ichioka, K; Kajita, Y; Kobayashi, T; Matsui, Y; Nishiyama, H; Nishizawa, K; Ogawa, O; Saito, R; Watanabe, J | 1 |
| Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
| Chevreau, C; Chinet-Charrot, P; Culine, S; Fléchon, A; Henry-Amar, M; Houédé, N; Joly, F; Noal, S; Priou, F; Rolland, F | 1 |
| Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Kanai, K; Kikuchi, E; Kodaira, K; Mikami, S; Miyajima, A; Nakashima, J; Ohigashi, T; Oya, M; Suzuki, E; Uchida, Y | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Hoshina, A; Kato, M; Onishi, T; Yabana, T | 1 |
| Fukumoto, I; Fukumoto, K; Imada, N; Itani, K; Kanemitsu, D; Kassai, K; Kobayashi, Y; Koyama, M; Miyagaki, T; Nakase, Y; Onishi, A; Sakamoto, K; Takagi, T; Takenaka, S | 1 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Rexer, H | 2 |
| Burt, H; Jackson, J; Tsallas, A | 1 |
| Bassi, PF; D'Agostino, D; Franchini, S; Palermo, G; Racioppi, M; Renier, D; Rosato, A; Volpe, A | 1 |
| Baras, AS; Bekiranov, S; Burke, DJ; Havaleshko, DM; Lee, J; Moon, K; Smith, SC; Theodorescu, D | 1 |
| Fukuta, F; Kitamura, H; Kunishima, Y; Masumori, N; Mutoh, M; Shigyo, M; Taguchi, K; Takahashi, A; Tanaka, T; Tsukamoto, T; Yanase, M | 1 |
| Alvarez-Berger, F; Au, JL; Bergdall, V; Chen, L; Couto, G; Kosarek, CE; Lu, Z; Lyness, G; Wang, J; Wientjes, MG; Xin, Y; Yeh, TK | 1 |
| Cho, IC; Chung, J; Joung, JY; Kim, EK; Kwon, WA; Lee, KH; Park, S; Park, WS; Seo, HK; Yoon, H | 1 |
| Cleves, A; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Barlow, LJ; Benson, MC; Laudano, MA; Mann, MJ; McKiernan, JM; Petrylak, DP | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Baba, S; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Banzato, A; Bassi, P; Campisi, M; Montagner, IM; Renier, D; Rosato, A; Zanovello, P; Zuccolotto, G | 1 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| de Vere White, R; Gao, T; Lam, KS; Lara, PN; Li, Y; Lin, TY; Luo, J; Pan, CX; Zhang, H | 1 |
| Abotouk, N; Halim, A | 1 |
| Brody, M; Cohen, S; Dabrow, M; Hudes, G; Lee, J; Litwin, S; Plimack, ER; Song, W; Tuttle, H; Vaughn, D; Wong, YN | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Mussari, S; Russo, L; Veccia, A | 1 |
| Gao, T; Goodwin, N; Lam, KS; Li, YP; Lin, TY; Luo, J; Pan, CX; White, Rde V; Zhang, H | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Eguchi, J; Hakariya, T; Kanetaka, H; Noguchi, M; Nomata, K; Sagara, Y; Toubu, S; Tsuda, S | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Baselga, J; Bellmunt, J; Clèries, R; Cos, J; Eres, N; Margarit, C; Murio, JE; Pérez, M; Ribas, A | 1 |
| Petrylak, DP | 1 |
| Beckett, L; DeVere-White, R; Folkins, AK; Gandour-Edwards, R; Lara, PN; LaSalle, JM; Li, Y; Meyers, FJ | 1 |
| Dreicer, R; Levitt, R; Manola, J; See, W; Vaughn, DJ; Wilding, G | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Enokida, H; Gotanda, T; Hanada, T; Imazono, Y; Inomata, K; Kishiye, T; Kubo, H; Nakagawa, M; Nishiyama, K; Oku, S; Suzuki, S; Tahara, Y | 1 |
| Hsu, SL; Tsai, KJ; Yang, CR; Yuan, SY | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Au, JL; Chen, D; Song, D; Wientjes, MG | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Chen, GW; Chen, YS; Chung, JG; Lu, HF; Wang, DY; Yang, CC | 1 |
| Araki, I; Furuya, Y; Takeda, M; Takihana, Y; Tanabe, N | 1 |
| Hussain, SA; James, ND | 1 |
| Dundr, P; Dvorácek, J; Pesl, M; Povýsil, C; Vítková, I | 1 |
| Enokida, H; Gotanda, T; Imazono, Y; Inomata, K; Kishiye, T; Kubo, H; Nakagawa, M; Nishiyama, K; Suzuki, S; Tachiwada, T | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Gschwend, JE; Hautmann, RE; Simon, J; Volkmer, B | 1 |
| Cha, YN; Choi, SC; Chung, HT; Han, WC; Jun, CD; Kim, EC; Kim, TH; Nah, YH; Oh, HM; Park, JS; Yoon, KH; Yun, KJ | 1 |
| Cheung, HW; Guan, XY; Lee, DT; Ling, MT; Tsao, SW; Wang, X; Wong, YC | 1 |
| Breton, P; Haller, M; Le Visage, C; Leong, K; Malavaud, B; Rioux-Leclercq, N | 1 |
| Aravantinos, G; Bamias, A; Deliveliotis, Ch; Dimopoulos, MA; Kalofonos, Ch; Karayiannis, A | 1 |
| Au, JL; Lu, Z; Tsai, M; Wientjes, MG; Yeh, TK | 1 |
| Comella, P; Crucitta, E; De Lena, M; Gebbia, V; Lorusso, V; Mancarella, S; Mangiameli, A; Manzione, L; Muci, D; Palmeri, S; Pezzella, G; Rosati, G; Silvestris, N; Sobrero, A | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Guardino, AE; Srinivas, S | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Litchy, S; Meluch, AA; Schnell, FM; Yost, K | 1 |
| Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N | 1 |
| Montie, JE | 1 |
| Cho, YH; Choi, YW; Chung, H; Kim, SW; Lee, SJ; Park, YT; Yoon, MS | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Au, JL; Gan, Y; Wientjes, MG | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Bartel, P; Ecke, TH; Koch, S; Ruttloff, J; Theissig, F | 1 |
| Cheng, AL; Hsu, CH; Huang, CY; Lin, CC; Pu, YS; Vogelzang, NJ | 1 |
| Bajorin, DF; Boyle, MG; Galsky, MD; Iasonos, A; Mironov, S; Scattergood, J | 1 |
| Beraldi, E; Gleave, M; Kamada, M; Muramaki, M; Rocchi, P; So, A | 1 |
| Albiol, S; Baselga, J; Bellmunt, J; Carles, J; Cecere, FL; Cuello, M; de la Cruz, JJ; Gallardo, E; Guillem, V; Mendez, P; Paz-Ares, L; Rosell, R; Taron, M | 1 |
| Cho, H; Conaway, M; Hampton, G; Havaleshko, DM; Lee, JK; Owens, CR; Theodorescu, D | 1 |
| Aaltonen, V; Koivunen, J; Laato, M; Peltonen, J | 1 |
| Choi, HY; Kang, WK; Kim, WS; Lee, HM; Lim, HY; Park, BB; Park, K; Uhm, JE | 1 |
| Aggarwal, BB; Kamat, AM; Sethi, G | 1 |
| Diestelhorst, A; Dunst, J; Fornara, P; Kühn, R; Kuhnt, T; Müller, AC; Scholz, HJ; Zietman, AL | 1 |
| Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
| Ando, M; Fujimoto, H; Fujiwara, Y; Katsumata, N; Komiyama, M; Kouno, T; Matsumoto, K; Matsuoka, N; Okajima, E; Shimizu, C; Yonemori, K | 1 |
| von der Maase, H | 2 |
| Hu, ZQ; Huang, DY; Liu, H; Liu, JH; Wang, ZH; Yang, N; Yang, WM; Ye, Q; Ye, ZQ; Zhang, X; Zhuang, QY | 1 |
| Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M | 1 |
| Vaughn, DJ | 3 |
| Chatta, GS; Chen, H; Dunn, RL; Glode, LM; Hussain, MH; Lara, PN; MacVicar, GR; Nanus, DM; Petrylak, DP; Smith, DC; Trump, DL; Vaishampayan, U | 1 |
| Fraig, M; Halushka, PV; Klein, J; Moussa, O; Riker, JM; Watson, DK | 1 |
| Bander, R; Bukacel, DG; Ibrahim, RB | 1 |
| Géczi, L | 1 |
| Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T | 1 |
| Rödel, C; Sauer, R; Weiss, C | 1 |
| Kodali, S; Ratnasabapathy, C; Sivamurthy, S | 1 |
| Burt, HM; Gleave, ME; Hadaschik, BA; Jackson, J; So, AI; Sowery, RD; ter Borg, MG | 1 |
| Roth, BJ | 4 |
| Dreicer, R; Einhorn, LH; Hudes, GR; Johnson, DH; Loehrer, PJ; Neuberg, D; Roth, BJ; Schultz, SM; Smith, JL | 1 |
| Amato, R; Hossan, E; Kilbourn, R; Logothetis, CJ; Tu, SM | 1 |
| Allam, N; Breillout, F; Debal, V; Gourdier, B; Manfait, M; Millot, JM; Morjani, H | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 1 |
| Bajorin, DF; Roth, BJ | 1 |
| Cox, C; Miller, A; Niell, H; Rangel, C | 1 |
| Arbuck, SG | 1 |
| Abi-Aad, AS | 1 |
| Dreicer, R; Gustin, DM; See, WA; Williams, RD | 1 |
| Beyer, J; Bokemeyer, C; Hartmann, JT; Jonas, U; Kanz, L; Kuczyk, MA; Truss, MC | 1 |
| Aronson, M; Kravtsov, V; Medalia, O; Moldavsky, T; Nativ, O; Ringel, I; Sabo, E | 1 |
| Aisner, J; Cortés-Funes, H | 1 |
| Gallagher, CJ; Johnson, PW; Oliver, RT; Papamichael, D; Waxman, J | 1 |
| Tannock, IF; Vukovic, V | 1 |
| Bex, A; Krege, S; Otto, T; Rübben, H; Walz, PH | 1 |
| Gross, AJ; Haschemi, R; Kallerhoff, M; Kugler, A; Ringert, RH; Zöller, G | 1 |
| Kolotas, C; Martin, T; Schneider, L; Strassmann, G; Vogt, HG; Zamboglou, N | 1 |
| Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ | 1 |
| Rowinsky, EK | 1 |
| Au, JL; Gan, Y; Kalns, J; Wientjes, MG | 1 |
| Brodowicz, T; Grbovic, M; Marberger, M; Pflüger, H; Schnack, B; Steger, G; Wiltschke, C; Zielinski, CC | 1 |
| Antoine, EC; Khayat, D | 1 |
| Curiel, DT; D'Amico, A; Frizelle, S; Grim, J; Kratzke, RA; Zhou, J | 1 |
| Orel, NF | 1 |
| Au, JL; Weaver, JR; Wientjes, MG | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Becker, A; Dunst, J; Heynemann, H; Weigel, C | 1 |
| Be, A; Lümmen, G; Otto, T; Raz, A; Rübben, H | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bakoyannis, C; Bamias, A; Deliveliotis, C; Dimopoulos, MA; Fountzilas, G; Georgoulias, V; Giannopoulos, A; Karayannis, A; Kosmidis, P; Kyriakakis, Z; Moulopoulos, LA; Pantazopoulos, D; Papadimitriou, C; Varkarakis, I; Zervas, A | 1 |
| Bajorin, DF | 1 |
| Bleicher, RJ; Singh, SV; Xia, H; Zaren, HA | 1 |
| deVere White, RW; Edelman, MJ; Gandour-Edwards, R; Meyers, FJ; Miller, TR; Williams, SG | 1 |
| Akaza, H; Hattori, K | 1 |
| Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Bellmunt, J; Cos, J; Lluis, JM; Margarit, C; Murio, JE; Ribas, A; Soler, C | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Cortés-Funes, H; González-Larriba, JL; Guillem, V; Paz-Ares, L; Tabernero, JM | 1 |
| Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; Karashima, T; McConkey, DJ; Radinsky, R; Slaton, JW | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Burch, PA; Camoriano, JK; Cha, SS; Kaur, JS; Pitot, HC; Richardson, RL; Sargent, DJ | 1 |
| Adams, JP; Dunn, NP; Kyker, JS; Lydick, K; Mahmood, SK; Malamud, FC; Nichols, RC; Sweetser, MG | 1 |
| Gallagher, CJ; Mason, M; McClaren, BR; Mulatero, C; Oliver, RT | 1 |
| Eisenberger, MA; Laufer, M; Schoenberg, MP | 1 |
| Bruns, CJ; Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; McConkey, DJ; Perrotte, P; Radinsky, R; Slaton, JW; Sweeney, P | 1 |
| Chang, YH; Chen, KK; Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Huang, WJ; Lin, AT; Liu, JH; Wang, WS; Yang, MH; Yen, CC | 1 |
| Malkowicz, SB; Vaughn, DJ | 2 |
| Du, W; Hussain, M; Redman, B; Smith, DC; Vaishampayan, U | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lu, SH; Pu, YS | 1 |
| Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Johnson, V; Meluch, AA; Morrissey, LH; O'Rourke, T; Ortega, G; Steis, RG | 1 |
| Soloway, MS | 1 |
| Kielb, SJ; Rubin, MA; Sanda, MG; Shah, NL | 1 |
| Adjei, AA; Bekele, L; Vidal Vazquez, M | 1 |
| Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C | 1 |
| Beaucage, SL; Benimetskaya, L; Benimetsky, S; Grajkowski, A; Guga, P; Halperin, AL; Maciaszek, A; Miller, P; Stein, CA; Wilk, A | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| de Wit, R | 1 |
| Broome, CM; Gutheil, JC; Hussain, M; Markowitz, AB; Vaughn, DJ | 1 |
| Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| Stadler, WM | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Misset, JL | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Dafni, U; Dimopoulos, MA; Dimopoulou, I; Galani, H; Roussos, C; Samakovii, A | 1 |
| Garcia, AM; Ishihara, H; Kowalczyk, JJ; Lewis, MD; Nagasu, T; Nakamura, K; Namiki, M; Yamaguchi, A; Yoshimatsu, K | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Garcia-Novio, F; Mateo, A; Mel, JR; Neira, J; Picallo, JA; Quintero-Aldana, G; Rico, M; Sousa-Escandon, A; Vazquez, S | 1 |
| Fujikawa, K; Fukuzawa, S; Iwamura, H; Matsui, Y; Oka, H; Takeuchi, H | 1 |
| Beyer, J; Bokemeyer, C; Hartmann, JT; Jonas, U; Kanz, L; Kollmannsberger, C; Kuczyk, MA; Truss, MC | 1 |
| Mimata, H; Miyamoto, E; Nomura, T; Nomura, Y; Shibasaki, F; Shitashige, M; Yamamoto, H | 1 |
| Chen, Y; Dilley, J; Li, Y; Ramesh, N; Working, P; Yu, DC; Zhang, J | 1 |
41 review(s) available for paclitaxel and Bladder Cancer
| Article | Year |
|---|---|
T-cell lymphoma secondary to checkpoint inhibitor therapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Humans; Immunotherapy; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Paclitaxel; Pleural Neoplasms; Prognosis; Urinary Bladder Neoplasms | 2020 |
[Advanced bladder cancer : From chemo- to immunotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Humans; Immunotherapy; Neoplasm Metastasis; Paclitaxel; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2018 |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Methotrexate; Nivolumab; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
A Case of Plasmacytoid Variant of Bladder Cancer With a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Humans; Male; Paclitaxel; Penile Neoplasms; Treatment Outcome; Ultrasonography; Urinary Bladder Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
New therapeutical approaches for non muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Humans; Hyaluronic Acid; Immunotherapy; Mitoxantrone; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
The systemic treatment of advanced and metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2003 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Metastatic squamous cell carcinoma of the urachus.
Topics: Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoplasm Metastasis; Paclitaxel; Tomography, X-Ray Computed; Urachus; Urinary Bladder Neoplasms | 2007 |
The role of paclitaxel in the therapy of bladder cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Palliative chemotherapy in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Preliminary experience with paclitaxel in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Staging; Paclitaxel; Pyrimidines; Trimetrexate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Ifosfamide in the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Gallium; Humans; Ifosfamide; Multicenter Studies as Topic; Paclitaxel; Remission Induction; Renal Insufficiency; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 1996 |
The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Germinoma; Humans; Male; Paclitaxel; Testicular Neoplasms; Urinary Bladder Neoplasms | 1996 |
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Paclitaxel; Urinary Bladder Neoplasms | 1997 |
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Endometrial Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphoma; Male; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Platinum Compounds; Sarcoma, Kaposi; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 1997 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
Review and outlook for the role of paclitaxel in urothelial carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Neoplasm Metastasis; Paclitaxel; Urinary Bladder Neoplasms | 1999 |
Paclitaxel in the treatment of advanced urothelial cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Paclitaxel; Urinary Bladder Neoplasms | 2000 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Paclitaxel and carboplatin in bladder cancer: recent developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Paclitaxel; Urinary Bladder Neoplasms | 2000 |
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Recent developments in chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2001 |
[New developments in chemotherapy for metastasized bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
Topics: Antineoplastic Agents, Phytogenic; Humans; Male; Paclitaxel; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms | 1998 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
74 trial(s) available for paclitaxel and Bladder Cancer
| Article | Year |
|---|---|
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Europe; Female; Humans; Hyaluronic Acid; Male; Middle Aged; Paclitaxel; Prospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Methotrexate; Neoadjuvant Therapy; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Everolimus; Humans; Paclitaxel; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
Topics: Biosimilar Pharmaceuticals; Carcinoma, Transitional Cell; Humans; Paclitaxel; Trastuzumab; Urinary Bladder Neoplasms | 2023 |
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2020 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cystectomy; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Paclitaxel; Radiation Injuries; Trastuzumab; Treatment Outcome; Urethra; Urinary Bladder Neoplasms | 2017 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Canada; Carcinoma; Chemistry, Pharmaceutical; Disease-Free Survival; Drug Administration Schedule; Drug Carriers; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Proportional Hazards Models; Time Factors; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Albumins; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Treatment Failure; Urinary Bladder Neoplasms | 2014 |
rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Core Binding Factor Alpha 2 Subunit; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Gene Targeting; Genetic Markers; Genetic Variation; Humans; MicroRNAs; Paclitaxel; Polymorphism, Single Nucleotide; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Albumins; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Male; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; bcl-X Protein; Carcinoma; Combined Modality Therapy; Disease Models, Animal; Humans; Kidney; Oligonucleotides, Antisense; Paclitaxel; Rats; Rats, Nude; Urinary Bladder Neoplasms; Urologic Neoplasms | 2009 |
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Female; Humans; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Paclitaxel; Urethra; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2009 |
Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.
Topics: Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Quality of Life; Urinary Bladder Neoplasms | 2009 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
[Second line AUO study AB35/09 of metastasized urothelial cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Everolimus; Humans; Paclitaxel; Sirolimus; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; BCG Vaccine; Biopsy, Needle; Carcinoma in Situ; Cystoscopy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyaluronic Acid; Italy; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2011 |
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Ifosfamide; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2011 |
A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Treatment Failure; Urinary Bladder Neoplasms | 2011 |
Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2011 |
[Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Everolimus; Humans; Paclitaxel; Sirolimus; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Cetuximab; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2012 |
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Paclitaxel; Prognosis; Survival Analysis; Urinary Bladder Neoplasms | 2002 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2004 |
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
A nonplatinum combination in metastatic transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms | 2005 |
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vitamin B Complex | 2007 |
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2007 |
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Patient Selection; Platinum Compounds; Survival Analysis; Survivors; Treatment Failure; Urethral Neoplasms; Urinary Bladder Neoplasms | 2007 |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms | 2007 |
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2007 |
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Carcinoma, Transitional Cell; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Urinary Bladder Neoplasms | 1994 |
Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Pilot Projects; Urinary Bladder Neoplasms | 1995 |
Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Renal Insufficiency; Salvage Therapy; Urinary Bladder Neoplasms; Urothelium | 1996 |
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1997 |
Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Pertussis Vaccine; Remission Induction; Urinary Bladder Neoplasms | 1997 |
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Confidence Intervals; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Salvage Therapy; Sepsis; Urinary Bladder Neoplasms | 1997 |
Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Leukopenia; Neoplasm Metastasis; Paclitaxel; Thrombocytopenia; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 1998 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Tumor cell motility. A novel therapeutic target in bladder carcinoma, experimental and clinical results.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Movement; Female; Humans; Male; Mice; Mice, Inbred Strains; Middle Aged; Paclitaxel; Signal Transduction; Urinary Bladder Neoplasms; Virulence Factors, Bordetella | 1999 |
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Greece; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Remission Induction; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 1999 |
Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2000 |
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2000 |
Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Constipation; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Mouth Mucosa; Nausea; Paclitaxel; Peripheral Nervous System Diseases; Stomatitis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vomiting | 2000 |
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2002 |
136 other study(ies) available for paclitaxel and Bladder Cancer
| Article | Year |
|---|---|
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
[A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Wnt/β-Catenin Signaling Contributes to Paclitaxel Resistance in Bladder Cancer Cells with Cancer Stem Cell-Like Properties.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Paclitaxel; Urinary Bladder Neoplasms; Wnt Signaling Pathway | 2021 |
In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
Topics: Cisplatin; Deoxyuridine; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Methotrexate; Mitomycin; Paclitaxel; Phosphatidylinositol 3-Kinases; Tumor Microenvironment; Urinary Bladder Neoplasms; Vinblastine; von Willebrand Factor | 2022 |
RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy.
Topics: Cell Line, Tumor; Glutathione; Humans; Nanoparticles; Oligopeptides; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Platinum; Polyethylene Glycols; Prodrugs; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Paclitaxel; Proton Pump Inhibitors; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Paclitaxel; Urinary Bladder Neoplasms | 2023 |
Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Topics: Aged; B7-H1 Antigen; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Creatinine; Disease Progression; Female; Follow-Up Studies; Humans; Immune Checkpoint Inhibitors; Incidence; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Time Factors; Tumor Burden; Urinary Bladder Neoplasms | 2020 |
Use of oral paclitaxel for the treatment of bladder tumors in dogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dog Diseases; Dogs; Female; Male; Paclitaxel; Urinary Bladder Neoplasms | 2020 |
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Down-regulation of autophagy-associated protein increased acquired radio-resistance bladder cancer cells sensitivity to taxol.
Topics: Autophagy; Cell Line, Tumor; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Humans; Paclitaxel; Radiation Tolerance; Urinary Bladder Neoplasms | 2021 |
In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Endometrial Neoplasms; Female; Gene Regulatory Networks; Genes, Tumor Suppressor; Genome, Human; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Mutation; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2021 |
Circadian clock protein CRY1 prevents paclitaxel‑induced senescence of bladder cancer cells by promoting p53 degradation.
Topics: Cell Line, Tumor; Cellular Senescence; Circadian Clocks; Circadian Rhythm; Cisplatin; Cryptochromes; Drug Resistance, Neoplasm; Humans; Paclitaxel; Proteolysis; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53; Ubiquitination; Urinary Bladder Neoplasms | 2021 |
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2021 |
Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Paclitaxel; Prognosis; Proportional Hazards Models; Tubulin; Urinary Bladder Neoplasms | 2018 |
Effects of paclitaxel combined with miR-448 on growth and proliferation of bladder cancer EJ cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Urinary Bladder Neoplasms | 2018 |
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MAP Kinase Signaling System; Mice; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Cetuximab in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Male; Paclitaxel; Urinary Bladder Neoplasms | 2013 |
Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Male; Paclitaxel; Urinary Bladder Neoplasms | 2013 |
A new approach to second-line therapy for urothelial cancer?
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Reply to S. Buti and S. Culine.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Male; Paclitaxel; Urinary Bladder Neoplasms | 2013 |
Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Commentary on "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma." Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Male; Paclitaxel; Urinary Bladder Neoplasms | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Male; Paclitaxel; Urinary Bladder Neoplasms | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway.
Topics: Amino Acid Oxidoreductases; Animals; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Models, Biological; Nuclear Proteins; Oxidative Stress; Paclitaxel; Protein-Lysine 6-Oxidase; Reproducibility of Results; Ribonucleoproteins; RNA, Messenger; RNA, Small Interfering; Serine-Arginine Splicing Factors; Signal Transduction; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Kidney Transplantation; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Paclitaxel; Platinum; Signal Transduction; Transcription Factor RelA; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Methacrylates; Mice, Inbred C3H; Neoplasm Transplantation; Paclitaxel; Phosphorylcholine; Solubility; Tumor Burden; Urinary Bladder Neoplasms | 2015 |
Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Colorimetry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA Processing, Post-Transcriptional; Urinary Bladder Neoplasms | 2015 |
[A CASE OF UROTHELIAL CARCINOMA OF THE URINARY BLADDER WITH SQUAMOUS DIFFERENTIATION RESPONDING TO PACLITAXEL AND CARBOPLATIN NEOADJUVANT CHEMOTHERAPY].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Recurrence; Tomography, X-Ray Computed; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2015 |
Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Survival; DNA Adducts; Drug Synergism; Humans; Paclitaxel; Urinary Bladder Neoplasms | 2015 |
[The Combination Therapy of Gemcitabine Plus Paclitaxel Induced Complete Response in a Tongue Skin Brain Metastasis of Bladder Carcinoma: A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Skin Neoplasms; Tongue Neoplasms; Urinary Bladder Neoplasms | 2015 |
Promotion of mitotic catastrophe via activation of PTEN by paclitaxel with supplement of mulberry water extract in bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitosis; Morus; Paclitaxel; Plant Extracts; PTEN Phosphohydrolase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Transplantation; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disulfides; Drug Carriers; Drug Delivery Systems; Humans; Mice; Micelles; Paclitaxel; Polyethylene Glycols; Urinary Bladder Neoplasms | 2016 |
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Agents; beta Catenin; Carboplatin; Carcinoma; Cell Nucleus; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Mutation; Paclitaxel; Urinary Bladder Neoplasms; Urothelium; Wnt Proteins | 2009 |
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Humans; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polyethyleneimine; Urinary Bladder Neoplasms | 2009 |
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Combined Modality Therapy; Cystectomy; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Karnofsky Performance Status; Male; Paclitaxel; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2009 |
Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells.
Topics: Antineoplastic Agents, Phytogenic; bcl-Associated Death Protein; Carcinoma, Transitional Cell; Caspase 3; Chromones; Cytochromes c; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mitochondrial Membranes; Morpholines; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Urinary Bladder Neoplasms | 2009 |
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Selection; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Epirubicin; Humans; Hydrogen-Ion Concentration; Paclitaxel; Photochemotherapy; Urinary Bladder Neoplasms; Urocanic Acid | 2009 |
Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Dicumarol; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoblotting; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Signal Transduction; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Urothelium | 2010 |
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2009 |
Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Cell Line, Tumor; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Tocopherols; Urinary Bladder Neoplasms | 2010 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinoembryonic Antigen; Disease Progression; Female; Humans; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
[A case of metastatic bladder cancer occurring after surgery for differentiated gastric cancer controlled by combination therapy of paclitaxel/S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2010 |
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Biological Transport; Docetaxel; Drug Carriers; Drug Compounding; Glycerol; In Vitro Techniques; Male; Micelles; Nanoparticles; Paclitaxel; Pharmaceutical Vehicles; Polyesters; Polyethylene Glycols; Polysorbates; Swine; Taxoids; Tissue Distribution; Urinary Bladder; Urinary Bladder Neoplasms | 2011 |
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.
Topics: Algorithms; Aminoacridines; Antineoplastic Agents; Biomarkers, Pharmacological; Computer Simulation; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Models, Genetic; Paclitaxel; Saccharomyces cerevisiae; Statistics, Nonparametric; Transcription, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Dogs; Drug Delivery Systems; Gelatin; Humans; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Gentamicins; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Failure; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2011 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines.
Topics: Antineoplastic Agents; Biological Transport; Boron Compounds; Cell Line, Tumor; Cell Survival; Endocytosis; Fluorescent Dyes; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lysosomes; Microscopy, Confocal; Microtubules; Paclitaxel; Protein Binding; Urinary Bladder Neoplasms | 2013 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Daunorubicin; Dogs; Drug Carriers; Drug Delivery Systems; Fluorescent Dyes; Male; Mice; Mice, SCID; Micelles; Nanoparticles; Paclitaxel; Peptides, Cyclic; Tissue Distribution; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Maximum Tolerated Dose; Mice; Micelles; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
[Feasibility and change in the level of blood paclitaxel concentration after paclitaxel therapy for a hemodialysis patient with cisplatin resistant metastatic transitional cell cancer].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Salvage therapy for platinum-refractory urothelial cancer: designing new clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; Methotrexate; Paclitaxel; Patient Selection; Reproducibility of Results; Research Design; Salvage Therapy; Urinary Bladder Neoplasms | 2002 |
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Analysis; Urinary Bladder Neoplasms | 2002 |
Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Humans; Immunoblotting; Neoplasm Proteins; Paclitaxel; Polyisoprenyl Phosphate Sugars; Structure-Activity Relationship; Terpenes; Tubulin; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vault Ribonucleoprotein Particles | 2002 |
Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Caspases; Cell Division; Fas Ligand Protein; fas Receptor; Humans; Membrane Glycoproteins; Mitochondria; Mitosis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dimethyl Sulfoxide; Dogs; Dose-Response Relationship, Drug; Female; Male; Micelles; Paclitaxel; Solvents; Time Factors; Urinary Bladder Neoplasms | 2003 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
Paclitaxel (taxol) inhibits the arylamine N-acetyltransferase activity and gene expression (mRNA NAT1) and 2-aminofluorene-DNA adduct formation in human bladder carcinoma cells (T24 and TSGH 8301).
Topics: 4-Aminobenzoic Acid; Acetylation; Acetyltransferases; Antineoplastic Agents; Arylamine N-Acetyltransferase; Chromatography, High Pressure Liquid; DNA Adducts; Dose-Response Relationship, Drug; Female; Fluorenes; Humans; In Vitro Techniques; Isoenzymes; Male; Paclitaxel; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Drug Administration Schedule; Drug Monitoring; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Lung Neoplasms; Male; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2003 |
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2003 |
Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Immunoblotting; Paclitaxel; Structure-Activity Relationship; Terpenes; Urinary Bladder Neoplasms | 2003 |
[Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms | 2003 |
Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Progression; Female; Free Radical Scavengers; Macrophages; Male; Mice; Mice, Inbred C57BL; Mitosis; Nitric Oxide; Paclitaxel; Peritoneum; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells.
Topics: Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Helix-Loop-Helix Motifs; Humans; Inhibitory Concentration 50; Male; Nasopharyngeal Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transcription Factors; Tumor Cells, Cultured; Twist-Related Protein 1; Urinary Bladder Neoplasms; Vincristine | 2004 |
Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
Topics: Adhesives; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Drug Delivery Systems; Female; Mice; Mice, Inbred BALB C; Microspheres; Paclitaxel; Urinary Bladder Neoplasms | 2004 |
Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Dogs; Dose-Response Relationship, Drug; Drug Delivery Systems; Gelatin; Male; Micelles; Nanostructures; Nanotechnology; Paclitaxel; Polyethylene Glycols; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; X-Ray Diffraction | 2004 |
Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel.
Topics: Absorption; Administration, Intravesical; Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Female; Glycerides; Paclitaxel; Rabbits; Urinary Bladder Neoplasms | 2005 |
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Male; Ovarian Neoplasms; Paclitaxel; Prognosis; Tissue Culture Techniques; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Oligonucleotides, Antisense; Paclitaxel; RNA, Small Interfering; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2007 |
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Caveolin 1; Cisplatin; Databases as Topic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2007 |
Prediction of drug combination chemosensitivity in human bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Predictive Value of Tests; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.
Topics: Carbazoles; Cell Death; DNA Damage; Doxorubicin; Enzyme Inhibitors; G2 Phase; Humans; Indoles; Mitosis; Models, Biological; Paclitaxel; Protein Kinase C-alpha; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Salvage Therapy; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cell
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Membrane Proteins; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerases; Smoking; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |
Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Paclitaxel; Survival Analysis; Urethral Neoplasms; Urinary Bladder Neoplasms | 2007 |
[Antisense RNA of survivin gene enhances the taxol-induced apoptosis and sensitivity to chemotherapy drugs in bladder cancer cells: an in vitro experiment].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; RNA, Antisense; Survivin; Transfection; Urinary Bladder Neoplasms | 2007 |
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Tetrazoles; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Moving forward in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; ErbB Receptors; Gemcitabine; Humans; Methotrexate; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Neoplasm Invasiveness; Paclitaxel; Thromboxane-A Synthase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2008 |
Cross-reactivity between paclitaxel and hazelnut: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Corylus; Cross Reactions; Diphenhydramine; Drug Hypersensitivity; Female; Histamine H1 Antagonists; Humans; Hydrocortisone; Hypersensitivity, Immediate; Nut Hypersensitivity; Paclitaxel; Plant Proteins; Urinary Bladder Neoplasms | 2007 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Female; Mice; Mice, Nude; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
[Characterization of the mechanism of cross-resistance to vinca alkaloids and taxoids in the human J82 bladder tumor cell line].
Topics: Antineoplastic Agents; Carcinoma; Colchicine; Doxorubicin; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phenotype; Podophyllotoxin; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Taxol and taxotere in bladder cancer: in vitro activity and urine stability.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 1994 |
Paclitaxel: current developmental approaches of the National Cancer Institute.
Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Esophageal Neoplasms; Female; Germinoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; Sarcoma, Kaposi; United States; Urinary Bladder Neoplasms | 1995 |
Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Female; Mice; Mice, Inbred C3H; Organ Size; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
In vitro investigations of new therapeutic agents on bladder tumor cell lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Gallium; Humans; Methotrexate; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 1997 |
Pharmacologic effects of paclitaxel in human bladder tumors.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Transitional Cell; Cell Division; DNA; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Paclitaxel; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.
Topics: Adenoviridae; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; G1 Phase; Genes, p16; Genes, Retinoblastoma; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mesothelioma; Paclitaxel; Recombinant Proteins; Retinoblastoma Protein; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Culture Techniques; Drug Screening Assays, Antitumor; Floxuridine; Humans; Image Processing, Computer-Assisted; Mitomycin; Paclitaxel; Urinary Bladder Neoplasms | 1999 |
Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Paclitaxel; Radiation-Sensitizing Agents; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; DNA Damage; Drug Resistance, Neoplasm; Humans; Mitomycin; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Humans; Methotrexate; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2000 |
Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Time Factors; Urinary Bladder Neoplasms | 2000 |
Paclitaxel-induced stomal neuropathy: a unique cause of pain in a patient with ileal conduit.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Humans; Ileum; Male; Middle Aged; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Postoperative Complications; Surgical Stomas; Urinary Bladder Neoplasms; Urinary Diversion | 2000 |
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Cetuximab; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Down-Regulation; Endothelial Growth Factors; Endothelium; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Inhibitory Concentration 50; Interleukin-8; Lymphatic Metastasis; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Size; Paclitaxel; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Renal Insufficiency; Survival Analysis; Urinary Bladder Neoplasms | 2000 |
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2001 |
Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Synergism; Humans; Paclitaxel; Salvage Therapy; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo.
Topics: Amides; Animals; Antineoplastic Agents; Apoptosis; Butyrates; Cell Division; Docetaxel; Female; Genes, bcl-2; Humans; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Bladder tumor markers, intravesical therapy and systemic chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Death; Cell Line; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunohistochemistry; Mutation; Paclitaxel; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2001 |
Systemic chemotherapy in patients with renal failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Glomerulonephritis; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2001 |
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Blood Vessels; Blotting, Northern; Cadherins; Carcinoma, Transitional Cell; Cell Movement; Collagen; Collagenases; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Interferon-alpha; Interleukin-8; Laminin; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Prognosis; Proteoglycans; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Down-Regulation; Gene Deletion; Humans; Isoenzymes; Male; NF-kappa B; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-alpha; Proto-Oncogene Proteins c-bcl-2; Ribonuclease H; RNA, Messenger; Thionucleotides; Transcription Factor RelA; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Carbon Monoxide; Carboplatin; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung; Lung Diseases; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Pulmonary Diffusing Capacity; Respiratory Function Tests; Urinary Bladder Neoplasms | 2002 |
Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Methionine; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Protein Processing, Post-Translational; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2002 |
Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzimidazoles; Calcineurin Inhibitors; Caspase 3; Caspases; Cyclosporine; Drug Synergism; Enzyme Activation; Humans; Immunosuppressive Agents; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Staining and Labeling; Tacrolimus; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Topics: Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cytopathogenic Effect, Viral; Docetaxel; Drug Synergism; Gene Deletion; Genes, Regulator; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Taxoids; Urinary Bladder Neoplasms; Uroplakin II; Virus Replication; Xenograft Model Antitumor Assays | 2002 |